


Accepted Manuscript

Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma

C. Gustavo De Moraes, MD, MPH, Jeffrey M. Liebmann, MD, Leonard A. Levin, MD, PhD



PII: S1350-9462(16)30048-9

DOI: [10.1016/j.preteyeres.2016.10.001](https://doi.org/10.1016/j.preteyeres.2016.10.001)

Reference: JPRR 647

To appear in: *Progress in Retinal and Eye Research*

Received Date: 31 July 2016

Revised Date: 8 October 2016

Accepted Date: 17 October 2016

Please cite this article as: De Moraes, C.G., Liebmann, J.M., Levin, L.A., Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma, *Progress in Retinal and Eye Research* (2016), doi: 10.1016/j.preteyeres.2016.10.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Detection and Measurement of Clinically Meaningful Visual Field Progression in Clinical Trials for Glaucoma

C. Gustavo De Moraes, MD, MPH ^a

Jeffrey M. Liebmann, MD ^a

Leonard A. Levin, MD, PhD ^{b,c}

^a Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Medical Center, 635 W. 165th street, New York, New York, 10032, USA.

^b Department of Ophthalmology, McGill University, McGill Academic Eye Centre 5252 Boul de Maisonneuve West, 4th floor, Montreal, Quebec H4A 3S5, Canada.

^c Department of Ophthalmology and Visual Sciences, University of Wisconsin, 2880 University Avenue, Madison, Wisconsin, USA.

Disclosures:

CGDM: None; JML: Consultant; Allergan Inc., Alcon Inc., Bausch & Lomb, Inc, Quark, Inc., Aerie, Inc., LAL: Consultant on neuroprotection research to Aerie, GlaxoSmithKline, Inotek, Quark, and Regenera. Support for a previous version of this manuscript was provided by Merz Pharma.

Corresponding author:

Leonard A. Levin

McGill Academic Eye Centre

5252 Boul de Maisonneuve West, 4th floor

Montreal, Quebec H4A 3S5

Canada

Phone: (514) 843-1544

E-mail: leonard.levin@mcgill.ca

Download English Version:

<https://daneshyari.com/en/article/5705712>

Download Persian Version:

<https://daneshyari.com/article/5705712>

[Daneshyari.com](https://daneshyari.com)